AACR 2021: Advancing Bispecific Antibody Discovery using a Common Light Chain Immunoglobulin Humanized Mouse

AACR 2021: Advancing Bispecific Antibody Discovery using a Common Light Chain Immunoglobulin Humanized Mouse

The common challenges of bispecific therapeutic antibody discovery are immunogenicity and chain mispairing issues. Biocytogen’s RenLite^TM immunoglobulin humanized mouse is designed not only to overcome these two issues, but also to provide a full human heavy chain repertoire diversity. RenLite^TM mouse carries full human heavy chain VDJ loci and a fixed common human light chain VJ gene. The derived antibodies share the same light chain with different heavy chain variable domains. This technology dramatically simplifies the following heavy and light chain pairing process. Antibodies generated by RenLite^TM mice underwent natural selection, differentiation, and affinity maturation in vivo utilizing a human heavy chain repertoire, the potential of immunogenicity is minimized. RenLite^TM mice show robust immune response comparable to wild-type mice and RenLite^TM mice derived antibodies show a wide range of binding affinity including subnanomolar binding. RenLite^TM antibodies also showed strong in vivo efficacy against tumor growth in xenograft mouse models. In summary, RenLite^TM mouse is a powerful tool for advancing current bispecific or multispecific antibody discovery.